Simultaneous Prediction of Binding Capacity for Multiple Molecules of the HLA B44 Supertype 1

We selected for study a set of B44-supertype molecules collectively represented in >40% of the individuals in all major ethnicities (B*1801, B*4001, B*4002, B*4402, B*4403, and B*4501). The peptide-binding specificity of each molecule was characterized using single amino acid substitution analogues and nonredundant peptide libraries. In all cases, only peptide ligands with glutamic acid in position 2 were preferred. At the C terminus, each allele was associated with a unique but broad pattern of preferences, but all molecules tolerated hydrophobic/aliphatic (leucine, isoleucine, valine, methionine), aromatic (tyrosine, phenylalanine, tryptophan), and small (alanine, glycine, threonine) residues. Secondary anchor motifs were also defined for all molecules. Together, these features were used to define a B44 supermotif and a novel algorithm for calculating degeneracy scores that can be used to predict B44-supertype degenerate binders. Approximately 90% of the peptides with a B44 supermotif degeneracy score of >10 bound at least three of the six B44-supertype molecules studied with high affinity. Finally, a number of peptides derived from hepatitis B and C viruses, HIV, and Plasmodium falciparum have been identified that have degenerate B44 supertype-binding capacity. Taken together, these findings have important implications for epitope-based approaches to vaccination, immunotherapy, and the monitoring of immune responses.

[1]  J. Kalil,et al.  Influence of HLA class I- and class II-specific monoclonal antibodies on DR-restricted lymphoproliferative responses. I. Unseparated populations of effector cells. , 1983, Journal of immunology.

[2]  A. Kumar,et al.  Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response , 1997, The Journal of experimental medicine.

[3]  M F del Guercio,et al.  Several HLA alleles share overlapping peptide specificities. , 1995, Journal of immunology.

[4]  J. Sidney,et al.  Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism , 1999, Immunogenetics.

[5]  C. Bordignon,et al.  Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain. , 1994, Tissue antigens.

[6]  A Sette,et al.  Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.

[7]  N. Suciu-Foca,et al.  Naturally processed HLA class I bound peptides from c-myc-transfected cells reveal allele-specific motifs. , 1993, Journal of immunology.

[8]  J. Sidney,et al.  Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. , 1999, Human immunology.

[9]  Taku Suto,et al.  An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries , 2000, Immunogenetics.

[10]  J. Sidney,et al.  HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. , 1998, Current opinion in immunology.

[11]  J. Sidney,et al.  Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.

[12]  John Sidney,et al.  Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules , 2003, Bioinform..

[13]  S. Burrows,et al.  Identification of cytotoxic T cell epitopes within Epstein‐Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype‐restricted immune recognition of EBV‐infected cells by LMP1‐specific cytotoxic T lymphocytes , 1998, European journal of immunology.

[14]  A Sette,et al.  Definition of specific peptide motifs for four major HLA-A alleles. , 1994, Journal of immunology.

[15]  D. Moss,et al.  Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.

[16]  P. Parham,et al.  Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. , 1999, Journal of immunology.

[17]  V. Gnau,et al.  Peptide motifs of HLA-B58, B60, B61, and B62 molecules , 2004, Immunogenetics.

[18]  B. Walker,et al.  Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. , 1996, The Journal of infectious diseases.

[19]  J. Skolnick,et al.  Application of an artificial neural network to predict specific class I MHC binding peptide sequences , 1998, Nature Biotechnology.

[20]  D. R. Madden,et al.  Identification of self peptides bound to purified HLA-B27 , 1991, Nature.

[21]  R W Chesnut,et al.  Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. , 1997, The Journal of clinical investigation.

[22]  Alessandro Sette,et al.  Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity1 , 2001, The Journal of Immunology.

[23]  S. H. van der Burg,et al.  Analogues of CTL epitopes with improved MHC class‐I binding capacity elicit anti‐melanoma CTL recognizing the wild‐type epitope , 1997, International journal of cancer.

[24]  Xiping Wei,et al.  Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.

[25]  Effie W Petersdorf,et al.  Nomenclature for factors of the HLA system, 2002. , 2002, Human immunology.

[26]  J. Frelinger,et al.  Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[28]  M F del Guercio,et al.  Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. , 1995, Journal of immunology.

[29]  F. Chisari,et al.  HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis , 1993, The Journal of experimental medicine.

[30]  F. Marincola,et al.  Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. , 1996, Journal of immunology.

[31]  M. Torres,et al.  Nomenclature for factors of the HLA system. , 2011, Bulletin of the World Health Organization.

[32]  John Sidney,et al.  Measurement of MHC/Peptide Interactions by Gel Filtration , 1999, Current protocols in immunology.

[33]  R. Offringa,et al.  Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma , 1999, European journal of immunology.

[34]  P. Romero,et al.  A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3 , 2005, Immunogenetics.

[35]  John Sidney,et al.  Identification of Novel HLA-A2-Restricted Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Epitopes Predicted by the HLA-A2 Supertype Peptide-Binding Motif , 2001, Journal of Virology.

[36]  A Sette,et al.  Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. , 1996, Immunology today.

[37]  John Sidney,et al.  Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes , 1997, Immunogenetics.

[38]  John Sidney,et al.  Definition of the Mamu A*01 Peptide Binding Specificity: Application to the Identification of Wild-Type and Optimized Ligands from Simian Immunodeficiency Virus Regulatory Proteins1 , 2000, The Journal of Immunology.

[39]  G Hermanson,et al.  Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. , 1995, Journal of immunology.

[40]  C. Bony,et al.  Identification in humans of HPV‐16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA‐B18 and determination of the HLA‐B18‐specific binding motif , 2000, European journal of immunology.

[41]  Todd M. Allen,et al.  Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. , 1998, Journal of immunology.

[42]  H. Rammensee,et al.  Definition of peptide binding motifs amongst the HLA-A*30 allelic group. , 2000, Tissue antigens.

[43]  J. Berzofsky,et al.  Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  J. Sidney,et al.  Conserved MHC Class I Peptide Binding Motif Between Humans and Rhesus Macaques1 , 2000, The Journal of Immunology.

[45]  A. Sette,et al.  The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.

[46]  C. Bordignon,et al.  Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. , 1996, Journal of immunology.

[47]  A Sette,et al.  Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. , 2001, Human immunology.

[48]  K. Parker,et al.  Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. , 1995, Biochemistry.

[49]  Naoki Abe,et al.  Empirical Evaluation of a Dynamic Experiment Design Method for Prediction of MHC Class I-Binding Peptides1 , 2002, The Journal of Immunology.

[50]  A Sette,et al.  Two complementary methods for predicting peptides binding major histocompatibility complex molecules. , 1997, Journal of molecular biology.

[51]  B. Malissen,et al.  Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. , 2008, Tissue antigens.

[52]  H. Zinszner,et al.  Nucleotide sequence of the HLA-A26 class I gene: identification of specific residues and molecular mapping of public HLA class I epitopes. , 1990, Human immunology.

[53]  A Sette,et al.  Human class I supertypes and CTL repertoires extend to chimpanzees. , 1998, Journal of immunology.

[54]  M F del Guercio,et al.  Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. , 1996, Journal of immunology.

[55]  E. Coligan Current protocols in immunology , 1991 .

[56]  G. Chelvanayagam A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities , 1996, Immunogenetics.

[57]  J. Sidney,et al.  Characterization of the Peptide-Binding Specificity of Mamu-B*17 and Identification of Mamu-B*17-Restricted Epitopes Derived from Simian Immunodeficiency Virus Proteins1 , 2002, The Journal of Immunology.

[58]  A. Sette,et al.  Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells , 1998, International journal of cancer.

[59]  A. Sette,et al.  Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. , 1998, Journal of immunology.

[60]  B. Walker,et al.  Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. , 1997, Journal of immunology.

[61]  M F del Guercio,et al.  Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. , 1996, Human immunology.

[62]  J. Berzofsky,et al.  Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. , 1998, The Journal of clinical investigation.

[63]  P. Flores-Villanueva,et al.  Identification of most frequent HLA class I antigen specificities in Botswana: relevance for HIV vaccine design. , 2001, Human immunology.

[64]  J. Sidney,et al.  Identification of Five Different Patr Class I Molecules That Bind HLA Supertype Peptides and Definition of Their Peptide Binding Motifs1 , 2000, The Journal of Immunology.

[65]  P. Travers,et al.  Prediction of an HLA-B44 binding motif by the alignment of known epitopes and molecular modeling of the antigen binding cleft , 2004, Immunogenetics.

[66]  T. Boon,et al.  A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes , 1996, European journal of immunology.

[67]  P. Coulie,et al.  A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 , 1994, European journal of immunology.

[68]  F. Marincola,et al.  Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.

[69]  K. Parker,et al.  Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. , 1992, Journal of immunology.

[70]  B. Drénou,et al.  QUANTIFICATION AND MOLECULAR ANALYSIS OF PLASMATIC HLA‐BCw MOLECULES WITH A LOCUS B AND Cw HLA SPECIFIC mAb (B1.23.2mAb) , 1995, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[71]  Todd M. Allen,et al.  Gorillas with Spondyloarthropathies Express an MHC Class I Molecule with Only Limited Sequence Similarity to HLA-B27 that Binds Peptides with Arginine at P21 , 2001, The Journal of Immunology.

[72]  M. Bonneville,et al.  T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis , 1996, The Journal of experimental medicine.

[73]  R W Chesnut,et al.  Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. , 1997, Immunity.

[74]  A Sette,et al.  Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. , 1999, Journal of immunology.